Universities of Cologne
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1388-01-01
- Employees
- 251
- Market Cap
- -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 46
- Registration Number
- NCT00404092
- Locations
- 🇧🇪
University Hospital Gasthuisberg, Leuven, Belgium
🇩🇪Klinikum der Universität zu Köln, Köln, Germany
🇩🇪Charité - Campus Benjamin Franklin, Berlin, Germany
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
Phase 3
Completed
- Conditions
- Hodgkin DiseaseMultiple MyelomaNon-Hodgkin LymphomaBacteremia
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 66
- Registration Number
- NCT00398411
- Locations
- 🇩🇪
Klinikum der Universität zu Köln, Köln, Germany
Whole Body Vibration - a New Therapeutic Approach to Improve Muscle Function in CF
Not Applicable
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2006-10-16
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 10
- Registration Number
- NCT00388466
- Locations
- 🇩🇪
CF Center Cologne, University Children's Hospital, Cologne, Germany
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
Phase 2
Completed
- Conditions
- Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- University of Cologne
- Registration Number
- NCT00346684
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
LDL Receptor Under Ezetimibe and Simvastatin
Phase 4
Completed
- Conditions
- Healthy Men
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 60
- Registration Number
- NCT00317993
- Locations
- 🇩🇪
Medizinische Klinik II und Poliklinik für Innere Medizin, Cologne, Germany
A Clinical Trial on the Antipsychotic Properties of Cannabidiol
Phase 2
Completed
- Conditions
- SchizophreniaPsychotic Disorders
- Interventions
- Drug: Cannabidiol/PlaceboDrug: Placebo/Cannabidiol
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 29
- Registration Number
- NCT00309413
- Locations
- 🇩🇪
University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne, NRW, Germany
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
Phase 2
Completed
- Conditions
- Hodgkin´s Lymphoma
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 65
- Registration Number
- NCT00284271
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
HD11 for Intermediate Stages
Phase 3
Completed
- Conditions
- Hodgkin´s Lymphoma
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1395
- Registration Number
- NCT00264953
HD10 for Early Stages
Phase 3
Completed
- Conditions
- Hodgkin´s Lymphoma
- Interventions
- Radiation: 20 Gy IF-RTRadiation: 30 Gy IF-RT
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1370
- Registration Number
- NCT00265018
HD12 for Advanced Stages
Phase 3
Completed
- Conditions
- Hodgkin´s Lymphoma
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- University of Cologne
- Registration Number
- NCT00265031
© Copyright 2025. All Rights Reserved by MedPath